Hyderabad-based CDMO making pharma intermediates, APIs, ADC payloads & oligonucleotides for global innovators.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 13 | 25 | 25 | 25 | 25 | 25 | 38 | 38 |
| Reserves | 832 | 1.2k | 1.5k | 1.7k | 2.0k | 1.7k | 3.7k | 3.9k |
| Borrowings | 186 | 143 | 97 | 70 | 65 | 279 | 451 | 400 |
| Other Liabilities | 142 | 151 | 205 | 160 | 138 | 1.1k | 1.3k | 1.4k |
| Total Liabilities | 1.2k | 1.5k | 1.8k | 2.0k | 2.3k | 3.0k | 5.6k | 5.7k |
| AssetsFixed Assets | 357 | 441 | 534 | 663 | 670 | 1.7k | 3.1k | 3.4k |
| CWIP | 102 | 96 | 30 | 165 | 179 | 256 | 357 | 173 |
| Investments | 338 | 542 | 598 | 536 | 904 | 337 | 454 | 529 |
| Other Assets | 376 | 395 | 667 | 601 | 501 | 725 | 1.6k | 1.7k |
| Total Assets | 1.2k | 1.5k | 1.8k | 2.0k | 2.3k | 3.0k | 5.6k | 5.7k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 50 | 407 | 383 | 330 | 457 | 358 | 288 | 368 |
| Cash from Investing | -65 | -413 | -311 | -136 | -195 | -362 | -253 | -255 |
| Cash from Financing | 26 | 7 | -76 | -156 | -242 | -14 | 3 | -165 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -6 | 304 | 272 | 255 | 171 | 307 | 132 | 169 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (59.3×) and current (94.2×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -28.6% growth and a 59× exit, ₹442 only delivers your return if you pay ₹18. The price is currently baking in 28% growth.
EPS grows -28.6%/yr for 5 years, then fades to 6% over 2, exits at 59×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -28.6% | 3.35 |
| FY28 | -28.6% | 2.39 |
| FY29 | -28.6% | 1.71 |
| FY30 | -28.6% | 1.22 |
| FY31 | -28.6% | 0.87 |
| FY32 | -11.3% ·fade | 0.77 |
| FY33 | 6.0% ·fade | 0.82 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.